Becton Dickinson & Co (BDX) KPIs and segments
Close on Nov 16, 2026Market cap $58.96BP/E 65.4Yield 1.92%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Becton Dickinson · năm tài chính kết thúc September 30 (FY2026 ended September 30, 2026; Biosciences & Diagnostic Solutions spin-off completed February 9, 2026)
Nhìn nhanh KPI của Becton Dickinson: 58 chỉ số vận hành, trong đó có Consolidated Revenue Growth Bridge, New BD Continuing Operations — Organic Revenue và Remaining Performance Obligations (RPO), lấy từ 249 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Năm tài chính của Becton Dickinson kết thúc September 30 (FY2026 ended September 30, 2026; Biosciences & Diagnostic Solutions spin-off completed February 9, 2026) — Q4 FY26 = CQ3 2026 (quý dương lịch).
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Medical($M)2 | 3,154 | 2,927 | 2,760 | 2,615 | 2,837 | 2,558 | 2,449 | 2,230 | |||||
U S($M) | 1,904 | 1,743 | 1,653 | 1,615 | 1,667 | 1,508 | 1,429 | 1,360 | |||||
International($M) | 1,250 | 1,184 | 1,107 | 999 | 1,170 | 1,050 | 1,020 | 870 | |||||
Medical Essentials($M)2 | 1,675 | 1,647 | 1,595 | 1,602 | 1,573 | 1,586 | |||||||
U S($M) | 994 | 965 | 938 | 920 | 929 | 932 | |||||||
International($M) | 681 | 682 | 658 | 682 | 643 | 654 | |||||||
Interventional($M)2 | 1,414 | 1,357 | 1,330 | 1,368 | 1,328 | 1,264 | 1,257 | 1,260 | 1,240 | 1,292 | 1,188 | ||
U S($M) | 957 | 933 | 914 | 905 | 898 | 880 | 861 | 851 | 844 | 898 | 802 | ||
International($M) | 457 | 423 | 416 | 462 | 430 | 384 | 396 | 409 | 396 | 395 | 386 | ||
Connected Care($M)2 | 1,224 | 1,120 | 1,131 | 1,166 | 1,068 | 1,073 | |||||||
U S($M) | 926 | 840 | 857 | 885 | 817 | 818 | |||||||
International($M) | 297 | 280 | 275 | 281 | 251 | 255 | |||||||
Life Sciences($M)2 | 766 | 1,369 | 1,254 | 1,247 | 836 | 1,339 | 1,260 | 1,304 | 1,288 | ||||
International($M) | 466 | 757 | 714 | 673 | 470 | 742 | 714 | 724 | 701 | ||||
U S($M) | 300 | 611 | 539 | 574 | 365 | 598 | 546 | 579 | 587 | ||||
BioPharma Systems($M) | 670 | 590 | 429 | 629 | 575 | 418 | |||||||
U S($M) | 3,081 | 2,917 | 3,159 | 4,418 | 2,882 | 2,776 | 3,080 | 3,117 | 2,891 | 2,906 | 2,749 | ||
International($M) | 1,902 | 1,797 | 2,093 | 3,883 | 1,844 | 1,704 | 2,089 | 2,320 | 2,098 | 2,139 | 1,957 | ||
Medical Essentials($M) | 617 | 574 | 569 | 612 | 617 | 607 | |||||||
Interventional($M) | 565 | 579 | 561 | 579 | 549 | 565 | 561 | ||||||
Connected Care($M) | 395 | 347 | 352 | 417 | 353 | 336 | |||||||
BioPharma Systems($M) | 259 | 225 | 140 | 239 | 224 | 141 | |||||||
Life Sciences($M) | 159 | 240 | |||||||||||
Interventional($M) | 912 | 928 | 885 | 907 | 882 | 863 | 853 | ||||||
Medical Essentials($M) | 849 | 812 | 795 | 825 | 830 | 816 | |||||||
Connected Care($M) | 696 | 630 | 630 | 668 | 590 | 590 | |||||||
Life Sciences($M) | 373 | 451 | |||||||||||
BioPharma Systems($M) | 308 | 274 | 186 | 287 | 269 | 186 | |||||||
Medical($M) | 880 | 550 | 492 | 792 | 753 | 662 | 535 | ||||||
Life Sciences($M) | 391 | 377 | 383 | 421 | 387 | 415 | 372 | ||||||
Interventional($M) | 376 | 392 | 387 | 376 | 365 | 388 | 291 | ||||||
Life Sciences($M) | -6 | -9 | |||||||||||
Connected Care($M) | -12 | -16 | |||||||||||
Interventional($M) | -17 | -23 | |||||||||||
BioPharma Systems($M) | -29 | -21 | |||||||||||
Medical Essentials($M) | -40 | -35 | |||||||||||
Consolidated Revenue Growth Bridge — Volume & Mix YoY (%)(%)3 | 4.1% | 2.4% | 0.3% | 3.5% | 1.0% | 3.5% | 4.9% | 5.0% | 0.5% | ||||
Consolidated Revenue Growth Bridge — Pricing YoY (%)(%) | 0.3% | 0.2% | 0.1% | -0.5% | -0.1% | 0.4% | 0.3% | 0.6% | 2.0% | ||||
Consolidated Revenue Growth Bridge — Foreign Currency Translation YoY (%)(%) | 1.0% | 2.6% | 1.2% | 0.5% | -1.5% | 0.2% | -0.6% | -0.1% | 1.0% | ||||
Consolidated Revenue Growth Bridge — Total Revenue Change YoY (%)(%) | 5.4% | 5.2% | 1.6% | 10.4% | 4.5% | 9.8% | 2.3% | 4.6% | 2.6% | ||||
New BD Continuing Operations — Organic Revenue ($M)($M)4 | 4,835 | 4,448 | 4,223 | 4,062 | 4,559 | 4,264 | 4,200 | 3,864 | |||||
New BD Organic Revenue — FX-Neutral Growth YoY (%)(%) | 4.9% | 4.0% | 1.9% | 4.9% | |||||||||
New BD Organic Revenue — Reported Growth YoY (%)(%) | 6.1% | 4.3% | 0.6% | 5.1% | |||||||||
New BD Organic Revenue — Foreign Currency Impact ($M)($M) | 54 | 15 | -57 | 6 | |||||||||
New BD Continuing Operations — Reported Revenue ($M)($M)3 | 5,005 | 4,726 | 4,480 | 4,333 | 4,559 | 4,264 | 4,200 | 3,864 | |||||
New BD Reported Revenue — FX-Neutral Growth YoY (%)(%) | 8.5% | 10.4% | 8.1% | 11.9% | |||||||||
New BD Reported Revenue — Reported Growth YoY (%)(%) | 9.8% | 10.8% | 6.7% | 12.1% | |||||||||
Inorganic M&A Revenue Contribution (Advanced Patient Monitoring, $M)($M) | 170 | 278 | 257 | 271 | 74 | ||||||||
Remaining Performance Obligations (RPO) — Service & Pending Equipment Installations ($M)($M)3 | 2,300 | 2,300 | 2,500 | 2,800 | 2,500 | 2,400 | 2,300 | 2,300 | 2,300 | 2,300 | 2,200 | ||
Remaining Performance Obligations (RPO) — Minimum Consumable Commitments ($M)($M) | 2,000 | 2,000 | 2,400 | 2,300 | 2,300 | 2,200 | 2,000 | 2,100 | 2,100 | 2,100 | 2,200 | ||
Customer Contract Liabilities / Unearned Service Revenue ($M)($M) | 334 | 337 | 457 | 336 | 492 | 495 | 502 | 482 | 449 | 440 | 419 | ||
Customer Rebate Accrual Liabilities ($M)($M) | 860 | 880 | 933 | 817 | 825 | 822 | 813 | 749 | 646 | 593 | 597 | ||
Developed Markets Revenue ($M)($M)3 | 4,575 | 4,365 | 4,121 | 4,535 | 4,366 | 4,113 | 3,933 | 4,439 | 3,990 | ||||
Developed Markets — FX-Neutral Revenue Growth YoY (%)(%) | 5.4% | 5.5% | 2.5% | 1.1% | 1.6% | ||||||||
Developed Markets — Reported Revenue Growth YoY (%)(%) | 4.8% | 6.1% | 4.8% | 2.2% | 2.7% | ||||||||
Developed Markets — Foreign Currency Impact ($M)($M) | -25 | 27 | 90 | 47 | 40 | ||||||||
Emerging Markets Revenue ($M)($M)4 | 699 | 618 | 592 | 718 | 639 | 613 | 547 | 729 | 716 | ||||
Emerging Markets — FX-Neutral Revenue Growth YoY (%)(%) | 7.2% | -2.6% | 3.5% | -3.7% | 1.2% | ||||||||
Emerging Markets — Reported Revenue Growth YoY (%)(%) | 9.4% | 0.8% | 8.3% | -1.6% | 2.5% | ||||||||
Emerging Markets — Foreign Currency Impact ($M)($M) | 14 | 21 | 26 | 16 | 9 | ||||||||
Greater China Revenue ($M)($M)3 | 228 | 223 | 209 | 255 | 242 | 236 | 222 | 295 | 300 | ||||
Greater China — FX-Neutral Revenue Growth YoY (%)(%) | -9.5% | -10.0% | -9.8% | -13.9% | -5.3% | ||||||||
Greater China — Reported Revenue Growth YoY (%)(%) | -5.8% | -5.6% | -6.2% | -13.5% | -6.8% | ||||||||
Greater China — Foreign Currency Impact ($M)($M) | 9 | 10 | 8 | 1 | -5 | ||||||||
Medical Essentials Segment — Worldwide Revenue ($M)($M)7 | 1,786 | 1,675 | 1,647 | 1,595 | 1,686 | 1,602 | 1,573 | 1,586 | 1,609 | 1,590 | 1,565 | 1,498 | |
Medical Essentials Segment — FX-Neutral Revenue Growth YoY (%)(%) | 5.9% | 3.2% | 1.7% | -0.6% | 3.6% | 0.7% | 2.4% | 5.8% | |||||
Medical Essentials Segment — Reported Revenue Growth YoY (%)(%) | 5.9% | 4.5% | 4.7% | 0.6% | 4.8% | 0.8% | 0.5% | 5.8% | |||||
Medical Essentials Segment — Foreign Currency Translation Impact ($M)($M) | 21 | 47 | 19 | 19 | 1 | -30 | 1 | ||||||
Medical Essentials Segment — U.S. Revenue ($M)($M)1 | 1,048 | 994 | 965 | 938 | 988 | 920 | 929 | 932 | 933 | 909 | 898 | 873 | |
Medical Essentials Segment — U.S. Revenue Growth YoY (%)(%) | 6.0% | 8.0% | 3.9% | 0.6% | 5.9% | 1.3% | 3.5% | 6.8% | |||||
Medical Essentials Segment — International Revenue ($M)($M)2 | 738 | 681 | 682 | 658 | 697 | 682 | 643 | 654 | 676 | 681 | 667 | 626 | |
Medical Essentials Segment — International FX-Neutral Growth YoY (%)(%) | 5.8% | -3.2% | -1.4% | -2.3% | 0.4% | -0.1% | 0.9% | 4.3% | |||||
Medical Essentials Segment — International Reported Growth YoY (%)(%) | 5.8% | -0.1% | 6.0% | 0.6% | 3.2% | 0.1% | -3.5% | 4.4% | |||||
Medication Delivery Solutions (MDS) — Worldwide Revenue ($M)($M)5 | 1,256 | 1,164 | 1,163 | 1,128 | 1,202 | 1,132 | 1,117 | 1,124 | 1,147 | 1,123 | 1,107 | 1,052 | |
Medication Delivery Solutions (MDS) — FX-Neutral Revenue Growth YoY (%)(%) | 4.5% | 1.6% | 1.4% | -0.7% | 3.8% | 0.7% | 2.8% | 6.8% | 5.2% | 3.9% | 3.5% | 0.2% | |
Medication Delivery Solutions (MDS) — Reported Revenue Growth YoY (%)(%) | 4.5% | 2.8% | 4.1% | 0.3% | 4.8% | 0.8% | 0.9% | 6.9% | 4.4% | 3.4% | 3.5% | 1.2% | |
Medication Delivery Solutions (MDS) — Foreign Currency Translation Impact ($M)($M) | 13 | 31 | 12 | 12 | 1 | -20 | 1 | -8 | -6 | 10 | |||
Medication Delivery Solutions (MDS) — U.S. Revenue ($M)($M)1 | 764 | 720 | 712 | 693 | 728 | 680 | 687 | 694 | 689 | 670 | 662 | 639 | |
Medication Delivery Solutions (MDS) — U.S. Revenue Growth YoY (%)(%) | 4.9% | 5.9% | 3.7% | -0.2% | 5.7% | 1.4% | 3.7% | 8.6% | 5.0% | 6.8% | 7.6% | 3.1% | |
Medication Delivery Solutions (MDS) — International Revenue ($M)($M)2 | 493 | 444 | 451 | 435 | 474 | 452 | 430 | 430 | 458 | 453 | 445 | 413 | |
Medication Delivery Solutions (MDS) — International FX-Neutral Growth YoY (%)(%) | 3.9% | -4.7% | -2.2% | -1.7% | 0.9% | -0.3% | 1.3% | 4.1% | 5.5% | -2.0% | -4.0% | ||
Medication Delivery Solutions (MDS) — International Reported Growth YoY (%)(%) | 3.9% | -1.8% | 4.9% | 1.2% | 3.5% | -0.1% | -3.3% | 4.3% | 3.6% | -1.3% | -2.1% | -1.6% | |
Specimen Management (SM) — Worldwide Revenue ($M)($M)5 | 529 | 511 | 484 | 468 | 483 | 470 | 456 | 462 | 462 | 467 | 458 | 447 | |
Specimen Management (SM) — FX-Neutral Revenue Growth YoY (%)(%) | 9.4% | 7.0% | 2.5% | -0.3% | 3.3% | 0.6% | 1.4% | 3.3% | |||||
Specimen Management (SM) — Reported Revenue Growth YoY (%)(%) | 9.5% | 8.7% | 6.2% | 1.3% | 4.7% | 0.7% | -0.6% | 3.3% | |||||
Specimen Management (SM) — Foreign Currency Translation Impact ($M)($M) | 8 | 17 | 7 | 7 | 1 | -9 | |||||||
Specimen Management (SM) — U.S. Revenue ($M)($M)1 | 284 | 274 | 253 | 245 | 260 | 240 | 242 | 238 | 244 | 239 | 236 | 234 | |
Specimen Management (SM) — U.S. Revenue Growth YoY (%)(%) | 9.2% | 14.0% | 4.5% | 2.9% | 6.6% | 0.8% | 2.7% | 2.0% | |||||
Specimen Management (SM) — International Revenue ($M)($M)2 | 245 | 237 | 231 | 222 | 223 | 230 | 213 | 223 | 218 | 228 | 222 | 213 | |
Specimen Management (SM) — International FX-Neutral Growth YoY (%)(%) | 9.7% | -0.2% | 0.3% | -3.7% | -0.5% | 0.3% | 0.1% | 4.7% | |||||
Specimen Management (SM) — International Reported Growth YoY (%)(%) | 9.9% | 3.1% | 8.1% | -0.4% | 2.6% | 0.7% | -4.1% | 4.8% | |||||
Connected Care Segment — Worldwide Revenue ($M)($M)8 | 1,269 | 1,224 | 1,120 | 1,131 | 1,250 | 1,166 | 1,068 | 1,073 | 1,013 | 840 | 772 | 747 | |
Connected Care Segment — FX-Neutral Revenue Growth YoY (%)(%) | 2.1% | 4.4% | 3.2% | 4.7% | 22.5% | 38.2% | 39.7% | 43.3% | |||||
Connected Care Segment — Reported Revenue Growth YoY (%)(%) | 1.6% | 4.9% | 4.9% | 5.5% | 23.4% | 38.8% | 38.4% | 43.7% | |||||
Connected Care Segment — Foreign Currency Translation Impact ($M)($M) | -7 | 6 | 18 | 8 | 10 | 5 | -10 | 3 | |||||
Connected Care Segment — U.S. Revenue ($M)($M)1 | 940 | 926 | 840 | 857 | 949 | 885 | 817 | 818 | 791 | 680 | 609 | 594 | |
Connected Care Segment — U.S. Revenue Growth YoY (%)(%) | -1.0% | 4.6% | 2.9% | 4.8% | 20.0% | 30.2% | 34.1% | 37.7% | |||||
Connected Care Segment — International Revenue ($M)($M)2 | 330 | 297 | 280 | 275 | 301 | 281 | 251 | 255 | 222 | 160 | 162 | 153 | |
Connected Care Segment — International FX-Neutral Growth YoY (%)(%) | 11.9% | 3.9% | 4.5% | 4.7% | 31.3% | 72.1% | 60.7% | 65.3% | |||||
Connected Care Segment — International Reported Growth YoY (%)(%) | 9.6% | 5.9% | 11.6% | 7.7% | 35.7% | 75.1% | 54.6% | 67.0% | |||||
Connected Care — Organic Revenue Excl. APM Acquisition ($M)($M)2 | 1,079 | 888 | 811 | 801 | 1,013 | 840 | 772 | 747 | |||||
Connected Care Organic Revenue — FX-Neutral Growth YoY (%)(%) | 5.9% | 5.3% | 5.9% | 7.1% | |||||||||
Connected Care Organic Revenue — Reported Growth YoY (%)(%) | 6.6% | 5.7% | 5.1% | 7.3% | |||||||||
Medication Management Solutions (MMS) — Worldwide Revenue ($M)($M)5 | 952 | 915 | 829 | 835 | 974 | 888 | 811 | 801 | 939 | 840 | 772 | 747 | |
Medication Management Solutions (MMS) — FX-Neutral Revenue Growth YoY (%)(%) | -2.2% | 2.3% | 0.4% | 3.4% | 3.1% | 5.3% | 5.9% | 7.1% | 18.0% | 11.6% | 6.5% | 5.0% | |
Medication Management Solutions (MMS) — Reported Revenue Growth YoY (%)(%) | -2.3% | 3.0% | 2.2% | 4.1% | 3.8% | 5.7% | 5.1% | 7.3% | 17.9% | 11.5% | 6.7% | 5.7% | |
Medication Management Solutions (MMS) — Foreign Currency Translation Impact ($M)($M) | -1 | 6 | 14 | 6 | 6 | 3 | -6 | 2 | -1 | -1 | 1 | 5 | |
Medication Management Solutions (MMS) — U.S. Revenue ($M)($M)1 | 736 | 737 | 660 | 678 | 780 | 709 | 662 | 659 | 744 | 680 | 609 | 594 | |
Medication Management Solutions (MMS) — U.S. Revenue Growth YoY (%)(%) | -5.6% | 3.9% | -0.2% | 2.9% | 4.9% | 4.3% | 8.6% | 11.0% | 23.6% | 15.9% | 10.7% | 5.3% | |
Medication Management Solutions (MMS) — International Revenue ($M)($M)2 | 216 | 178 | 168 | 156 | 194 | 179 | 149 | 142 | 195 | 160 | 162 | 153 | |
Medication Management Solutions (MMS) — International FX-Neutral Growth YoY (%)(%) | 11.8% | -4.0% | 3.3% | 5.5% | -3.8% | 9.6% | -4.5% | -8.2% | 0.6% | -3.4% | -7.1% | 3.5% | |
Medication Management Solutions (MMS) — International Reported Growth YoY (%)(%) | 11.4% | -0.4% | 12.7% | 9.7% | -0.4% | 11.4% | -8.2% | -6.9% | 0.3% | -4.0% | -6.3% | 7.3% | |
Advanced Patient Monitoring (APM) — Worldwide Revenue ($M)($M)5 | 317 | 309 | 292 | 297 | 276 | 278 | 257 | 271 | 74 | 0 | 0 | 0 | |
Advanced Patient Monitoring (APM) — FX-Neutral Revenue Growth YoY (%)(%) | 17.3% | 11.2% | 12.0% | 8.8% | |||||||||
Advanced Patient Monitoring (APM) — Reported Revenue Growth YoY (%)(%) | 15.0% | 10.9% | 13.6% | 9.4% | |||||||||
Advanced Patient Monitoring (APM) — Foreign Currency Translation Impact ($M)($M) | -6 | -1 | 4 | 2 | 3 | 2 | -4 | 1 | |||||
Advanced Patient Monitoring (APM) — U.S. Revenue ($M)($M)1 | 203 | 189 | 180 | 178 | 169 | 176 | 155 | 159 | 47 | 0 | 0 | 0 | |
Advanced Patient Monitoring (APM) — U.S. Revenue Growth YoY (%)(%) | 20.5% | 7.4% | 15.9% | 12.4% | |||||||||
Advanced Patient Monitoring (APM) — International Revenue ($M)($M)2 | 114 | 120 | 112 | 119 | 107 | 102 | 102 | 113 | 27 | 0 | 0 | 0 | |
Advanced Patient Monitoring (APM) — International FX-Neutral Growth YoY (%)(%) | 12.2% | 17.8% | 6.2% | 3.7% | |||||||||
Advanced Patient Monitoring (APM) — International Reported Growth YoY (%)(%) | 6.4% | 17.1% | 10.0% | 5.1% | |||||||||
BioPharma Systems (formerly Pharmaceutical Systems) — Worldwide Revenue ($M)($M)5 | 748 | 670 | 590 | 429 | 702 | 629 | 575 | 418 | 677 | 594 | 570 | 431 | |
BioPharma Systems (formerly Pharmaceutical Systems) — FX-Neutral Revenue Growth YoY (%)(%) | 7.0% | 5.2% | -1.8% | 1.0% | 1.4% | 4.8% | 2.2% | -3.2% | 3.0% | 0.9% | 0.3% | 3.4% | |
BioPharma Systems (formerly Pharmaceutical Systems) — Reported Revenue Growth YoY (%)(%) | 6.5% | 6.6% | 2.5% | 2.7% | 3.7% | 5.8% | 0.9% | -3.2% | 2.7% | 0.1% | 0.6% | 5.4% | |
BioPharma Systems (formerly Pharmaceutical Systems) — Foreign Currency Translation Impact ($M)($M) | -4 | 9 | 25 | 7 | 16 | 6 | -7 | -2 | -4 | 1 | 8 | ||
BioPharma Systems (formerly Pharmaceutical Systems) — U.S. Revenue ($M)($M)1 | 238 | 204 | 178 | 150 | 228 | 178 | 149 | 104 | 187 | 158 | 157 | 127 | |
BioPharma Systems (formerly Pharmaceutical Systems) — U.S. Revenue Growth YoY (%)(%) | 4.7% | 14.2% | 19.4% | 45.0% | 21.5% | 13.2% | -5.1% | -18.5% | -0.4% | -15.4% | -9.0% | 6.9% | |
BioPharma Systems (formerly Pharmaceutical Systems) — International Revenue ($M)($M)2 | 509 | 467 | 411 | 279 | 475 | 451 | 426 | 314 | 490 | 437 | 413 | 304 | |
BioPharma Systems (formerly Pharmaceutical Systems) — International FX-Neutral Growth YoY (%)(%) | 8.1% | 1.6% | -9.2% | -13.5% | -6.3% | 1.7% | 5.0% | 3.2% | 4.4% | 8.3% | 4.5% | 2.0% | |
BioPharma Systems (formerly Pharmaceutical Systems) — International Reported Growth YoY (%)(%) | 7.3% | 3.6% | -3.4% | -11.2% | -3.1% | 3.1% | 3.2% | 3.2% | 4.0% | 7.2% | 4.8% | 4.8% | |
Interventional Segment — Worldwide Revenue ($M)($M)8 | 1,472 | 1,414 | 1,357 | 1,330 | 1,367 | 1,328 | 1,264 | 1,257 | 1,260 | 1,240 | 1,292 | 1,188 | |
Interventional Segment — FX-Neutral Revenue Growth YoY (%)(%) | 7.6% | 5.5% | 5.3% | 5.1% | 7.5% | 6.8% | -1.1% | 5.5% | 5.4% | 2.6% | 9.5% | 4.7% | |
Interventional Segment — Reported Revenue Growth YoY (%)(%) | 7.6% | 6.4% | 7.3% | 5.8% | 8.5% | 7.2% | -2.2% | 5.8% | 4.7% | 1.8% | 9.0% | 5.2% | |
Interventional Segment — Foreign Currency Translation Impact ($M)($M) | 12 | 26 | 10 | 13 | 4 | -14 | 4 | -8 | -10 | -6 | 6 | ||
Interventional Segment — U.S. Revenue ($M)($M)1 | 978 | 957 | 933 | 914 | 905 | 898 | 880 | 861 | 851 | 844 | 898 | 802 | |
Interventional Segment — U.S. Revenue Growth YoY (%)(%) | 8.0% | 6.6% | 6.0% | 6.2% | 6.4% | 6.5% | -1.9% | 7.4% | 3.0% | 2.1% | 10.4% | 2.5% | |
Interventional Segment — International Revenue ($M)($M)2 | 494 | 457 | 423 | 416 | 462 | 430 | 384 | 396 | 409 | 396 | 395 | 386 | |
Interventional Segment — International FX-Neutral Growth YoY (%)(%) | 6.9% | 3.3% | 3.6% | 2.6% | 9.8% | 7.6% | 0.8% | 1.5% | 10.5% | 3.7% | 7.3% | 9.6% | |
Interventional Segment — International Reported Growth YoY (%)(%) | 6.8% | 6.2% | 10.4% | 5.1% | 13.0% | 8.6% | -2.8% | 2.4% | 8.5% | 1.0% | 5.9% | 11.2% | |
Peripheral Intervention (PI) — Worldwide Revenue ($M)($M)5 | 577 | 552 | 515 | 485 | 530 | 512 | 481 | 473 | 502 | 488 | 489 | 454 | |
Peripheral Intervention (PI) — FX-Neutral Revenue Growth YoY (%)(%) | 8.3% | 6.1% | 4.0% | 1.4% | 4.3% | 4.5% | 0.1% | 3.8% | 4.9% | 2.6% | 5.0% | 4.1% | |
Peripheral Intervention (PI) — Reported Revenue Growth YoY (%)(%) | 8.8% | 7.8% | 7.1% | 2.6% | 5.6% | 4.8% | -1.5% | 4.1% | 4.1% | 1.5% | 4.3% | 4.8% | |
Peripheral Intervention (PI) — Foreign Currency Translation Impact ($M)($M) | 2 | 9 | 15 | 6 | 7 | 1 | -8 | 1 | -4 | -5 | -3 | 3 | |
Peripheral Intervention (PI) — U.S. Revenue ($M)($M)1 | 297 | 294 | 279 | 265 | 275 | 271 | 269 | 253 | 267 | 263 | 264 | 234 | |
Peripheral Intervention (PI) — U.S. Revenue Growth YoY (%)(%) | 8.3% | 8.4% | 3.9% | 5.1% | 2.9% | 2.9% | 1.9% | 7.8% | -0.4% | 2.8% | 3.3% | -0.7% | |
Peripheral Intervention (PI) — International Revenue ($M)($M)2 | 280 | 258 | 236 | 220 | 256 | 241 | 212 | 220 | 235 | 225 | 225 | 220 | |
Peripheral Intervention (PI) — International FX-Neutral Growth YoY (%)(%) | 8.4% | 3.5% | 4.1% | -2.8% | 5.8% | 6.4% | -1.9% | -0.4% | 11.5% | 2.4% | 7.0% | 9.8% | |
Peripheral Intervention (PI) — International Reported Growth YoY (%)(%) | 9.3% | 7.2% | 11.1% | -0.2% | 8.7% | 7.0% | -5.5% | 0.2% | 9.7% | 5.6% | 11.4% | ||
Urology and Critical Care (UCC) — Worldwide Revenue ($M)($M)5 | 473 | 440 | 430 | 427 | 437 | 422 | 400 | 389 | 390 | 375 | 424 | 365 | |
Urology and Critical Care (UCC) — FX-Neutral Revenue Growth YoY (%)(%) | 8.7% | 4.2% | 6.5% | 9.5% | 11.5% | 12.1% | -5.1% | 6.3% | 10.3% | 8.3% | 26.7% | 9.3% | |
Urology and Critical Care (UCC) — Reported Revenue Growth YoY (%)(%) | 8.2% | 4.2% | 7.5% | 9.8% | 12.2% | 12.5% | -5.8% | 6.6% | 9.7% | 7.4% | 26.1% | 9.5% | |
Urology and Critical Care (UCC) — Foreign Currency Translation Impact ($M)($M) | -2 | 4 | 1 | 3 | 2 | -3 | 1 | -2 | -3 | -2 | 1 | ||
Urology and Critical Care (UCC) — U.S. Revenue ($M)($M)1 | 382 | 357 | 351 | 339 | 341 | 334 | 323 | 306 | 306 | 297 | 347 | 287 | |
Urology and Critical Care (UCC) — U.S. Revenue Growth YoY (%)(%) | 11.9% | 7.1% | 8.6% | 10.9% | 11.6% | 12.4% | -6.8% | 6.6% | 9.4% | 9.1% | 31.9% | 10.8% | |
Urology and Critical Care (UCC) — International Revenue ($M)($M)2 | 92 | 82 | 79 | 88 | 97 | 88 | 77 | 83 | 84 | 78 | 78 | 78 | |
Urology and Critical Care (UCC) — International FX-Neutral Growth YoY (%)(%) | -2.7% | -6.9% | -2.3% | 4.0% | 11.1% | 10.8% | 2.6% | 5.4% | 13.8% | 5.6% | 8.2% | 4.0% | |
Urology and Critical Care (UCC) — International Reported Growth YoY (%)(%) | -5.0% | -6.7% | 3.0% | 5.5% | 14.7% | 12.7% | -1.3% | 6.8% | 11.0% | 1.4% | 5.4% | 5.0% | |
Surgery (SURG) — Worldwide Revenue ($M)($M)5 | 422 | 422 | 411 | 418 | 400 | 395 | 383 | 395 | 368 | 376 | 379 | 369 | |
Surgery (SURG) — FX-Neutral Revenue Growth YoY (%)(%) | 5.5% | 6.2% | 5.5% | 5.1% | 7.6% | 4.6% | 1.9% | 6.8% | 1.1% | -2.5% | -0.3% | 1.2% | |
Surgery (SURG) — Reported Revenue Growth YoY (%)(%) | 5.5% | 7.0% | 7.4% | 5.9% | 8.5% | 4.9% | 1.0% | 7.0% | 0.7% | -3.0% | -0.5% | 1.7% | |
Surgery (SURG) — Foreign Currency Translation Impact ($M)($M) | 3 | 7 | 3 | 3 | 1 | -3 | 1 | -2 | -2 | -1 | 2 | ||
Surgery (SURG) — U.S. Revenue ($M)($M)1 | 299 | 306 | 303 | 310 | 290 | 294 | 289 | 303 | 279 | 283 | 287 | 280 | |
Surgery (SURG) — U.S. Revenue Growth YoY (%)(%) | 3.2% | 4.3% | 4.9% | 2.3% | 4.0% | 3.6% | 0.5% | 8.0% | -0.1% | -4.8% | -2.6% | -2.3% | |
Surgery (SURG) — International Revenue ($M)($M)2 | 122 | 116 | 109 | 108 | 110 | 101 | 94 | 92 | 89 | 93 | 92 | 88 | |
Surgery (SURG) — International FX-Neutral Growth YoY (%)(%) | 11.7% | 11.7% | 7.3% | 14.3% | 18.9% | 7.7% | 6.1% | 2.9% | 5.0% | 5.1% | 7.5% | 14.4% | |
Surgery (SURG) — International Reported Growth YoY (%)(%) | 11.6% | 15.0% | 14.9% | 17.6% | 22.6% | 9.0% | 2.5% | 4.1% | 3.2% | 3.1% | 6.9% | 17.1% | |
Medical Essentials — Segment Operating Income ($M)($M)7 | 617 | 574 | 569 | 612 | 617 | 607 | |||||||
Medical Essentials — Segment Operating Margin (% of Segment Revenue)(%) | 36.8% | 34.8% | 35.6% | 38.2% | 39.3% | 38.3% | |||||||
Medical Essentials — Segment Cost of Products Sold ($M)($M)1 | 826 | 835 | 800 | 777 | 743 | 770 | |||||||
Medical Essentials — Segment Cost of Products Sold (% of Revenue)(%) | 49.3% | 50.7% | 50.1% | 48.5% | 47.0% | 48.5% | |||||||
Medical Essentials — Segment Selling & Administrative Expense ($M)($M)1 | 183 | 185 | 180 | 169 | 164 | 165 | |||||||
Medical Essentials — Segment Selling & Administrative (% of Revenue)(%) | 10.9% | 11.2% | 11.3% | 10.5% | 10.4% | 10.4% | |||||||
Medical Essentials — Segment Research & Development Expense ($M)($M)1 | 49 | 53 | 47 | 44 | 48 | 44 | |||||||
Medical Essentials — Segment R&D Expense (% of Revenue)(%) | 2.9% | 3.2% | 2.9% | 2.8% | 3.1% | 2.8% | |||||||
Medical Essentials — Segment Other Operating Expense ($M)($M)1 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
Medical Essentials — Segment Depreciation & Amortization ($M)($M) | 138 | 147 | 141 | 145 | 136 | 135 | |||||||
Medical Essentials — Segment Goodwill Balance ($M)($M) | 7,020 | 7,010 | 7,015 | 7,011 | |||||||||
Connected Care — Segment Operating Income ($M)($M)7 | 395 | 347 | 352 | 417 | 353 | 336 | |||||||
Connected Care — Segment Operating Margin (% of Segment Revenue)(%) | 32.3% | 31.0% | 31.1% | 35.8% | 33.0% | 31.3% | |||||||
Connected Care — Segment Cost of Products Sold ($M)($M)1 | 528 | 490 | 501 | 498 | 478 | 483 | |||||||
Connected Care — Segment Cost of Products Sold (% of Revenue)(%) | 43.2% | 43.7% | 44.3% | 42.7% | 44.8% | 45.0% | |||||||
Connected Care — Segment Selling & Administrative Expense ($M)($M)1 | 195 | 190 | 191 | 172 | 161 | 168 | |||||||
Connected Care — Segment Selling & Administrative (% of Revenue)(%) | 15.9% | 17.0% | 16.9% | 14.8% | 15.1% | 15.7% | |||||||
Connected Care — Segment Research & Development Expense ($M)($M)1 | 102 | 90 | 85 | 74 | 74 | 80 | |||||||
Connected Care — Segment R&D Expense (% of Revenue)(%) | 8.3% | 8.1% | 7.5% | 6.4% | 6.9% | 7.4% | |||||||
Connected Care — Segment Other Operating Expense ($M)($M)1 | -4 | -3 | -3 | -5 | -2 | -6 | |||||||
Connected Care — Segment Depreciation & Amortization ($M)($M) | 199 | 194 | 194 | 198 | 199 | 194 | |||||||
Connected Care — Segment Goodwill Balance ($M)($M) | 6,093 | 6,095 | 6,093 | 6,093 | |||||||||
BioPharma Systems — Segment Operating Income ($M)($M)7 | 259 | 225 | 140 | 239 | 224 | 141 | |||||||
BioPharma Systems — Segment Operating Margin (% of Segment Revenue)(%) | 38.6% | 38.1% | 32.6% | 38.1% | 38.9% | 33.7% | |||||||
BioPharma Systems — Segment Cost of Products Sold ($M)($M)1 | 362 | 316 | 243 | 342 | 306 | 232 | |||||||
BioPharma Systems — Segment Cost of Products Sold (% of Revenue)(%) | 54.0% | 53.6% | 56.6% | 54.4% | 53.2% | 55.4% | |||||||
BioPharma Systems — Segment Selling & Administrative Expense ($M)($M)1 | 31 | 32 | 29 | 29 | 28 | 29 | |||||||
BioPharma Systems — Segment Selling & Administrative (% of Revenue)(%) | 4.7% | 5.4% | 6.6% | 4.6% | 4.8% | 6.8% | |||||||
BioPharma Systems — Segment Research & Development Expense ($M)($M)1 | 18 | 17 | 18 | 18 | 18 | 17 | |||||||
BioPharma Systems — Segment R&D Expense (% of Revenue)(%) | 2.7% | 2.8% | 4.1% | 2.9% | 3.1% | 4.1% | |||||||
BioPharma Systems — Segment Other Operating Expense ($M)($M)1 | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
BioPharma Systems — Segment Depreciation & Amortization ($M)($M) | 42 | 27 | 34 | 29 | 32 | 31 | |||||||
BioPharma Systems — Segment Goodwill Balance ($M)($M) | 97 | 96 | 96 | 96 | |||||||||
Interventional — Segment Operating Income ($M)($M)7 | 565 | 579 | 561 | 579 | 549 | 565 | 561 | ||||||
Interventional — Segment Operating Margin (% of Segment Revenue)(%) | 39.9% | 42.7% | 42.1% | 41.3% | 44.7% | 44.6% | |||||||
Interventional — Segment Cost of Products Sold ($M)($M)1 | 502 | 429 | 445 | 461 | 446 | 401 | 404 | ||||||
Interventional — Segment Cost of Products Sold (% of Revenue)(%) | 35.5% | 31.6% | 33.5% | 33.6% | 31.7% | 32.1% | |||||||
Interventional — Segment Selling & Administrative Expense ($M)($M)1 | 277 | 277 | 262 | 254 | 271 | 236 | 237 | ||||||
Interventional — Segment Selling & Administrative (% of Revenue)(%) | 19.6% | 20.4% | 19.7% | 20.4% | 18.6% | 18.9% | |||||||
Interventional — Segment Research & Development Expense ($M)($M)1 | 70 | 72 | 63 | 73 | 63 | 63 | 56 | ||||||
Interventional — Segment R&D Expense (% of Revenue)(%) | 4.9% | 5.3% | 4.7% | 4.7% | 5.0% | 4.4% | |||||||
Interventional — Segment Other Operating Expense ($M)($M)1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Interventional — Segment Depreciation & Amortization ($M)($M) | 182 | 192 | 197 | 196 | 200 | 198 | 200 | ||||||
Interventional — Segment Goodwill Balance ($M)($M) | 12,734 | 12,755 | 12,767 | 12,764 | 12,756 | 12,687 | 12,663 | 12,729 | 12,681 | 12,692 | 12,708 | ||
BD Medical Segment (Legacy through FY2025) — Segment Operating Income ($M)1 | |||||||||||||
BD Life Sciences Segment (Legacy through FY2026Q1) — Segment Operating Income ($M)1 | |||||||||||||
Unallocated Corporate Expenses & Shared Functions ($M)($M) | 616 | 595 | 690 | 754 | 584 | 636 | 682 | ||||||
Adjusted Gross Profit — Non-GAAP ($M)($M)4 | 2,994 | 2,705 | 2,579 | 2,436 | 2,751 | 2,612 | 2,492 | 2,387 | |||||
Adjusted Gross Margin (% of Revenues)(%) | 56.8% | 54.3% | 54.7% | 53.4% | 55.0% | 55.3% | 55.6% | 54.8% | |||||
GAAP Gross Margin (% of Revenues)(%) | 51.1% | 46.4% | 45.7% | 45.9% | 47.3% | 47.3% | 41.5% | 43.3% | |||||
Reported GAAP Gross Profit — Continuing Operations ($M)($M) | 2,052 | 2,366 | 2,235 | 1,861 | 1,797 | ||||||||
Non-GAAP Adjustment: Purchase Accounting Amortization & Step-Up ($M)($M) | 346 | 384 | 383 | 377 | 544 | 562 | |||||||
Adjusted Operating Income — Non-GAAP ($M)($M)5 | 1,509 | 1,240 | 1,142 | 978 | 1,292 | 1,237 | 1,133 | 1,005 | |||||
Adjusted Operating Margin (% of Revenues)(%) | 28.6% | 24.9% | 24.2% | 21.2% | 25.8% | 26.2% | 25.3% | 23.6% | |||||
GAAP Operating Margin (% of Revenues)(%) | 19.6% | 13.3% | 2.0% | 10.5% | 10.7% | 15.6% | 8.6% | 8.8% | |||||
Reported GAAP Operating Income — Continuing Operations ($M)($M) | 468 | 536 | 740 | 383 | 282 | ||||||||
Adjusted SSG&A Expense — Non-GAAP ($M)($M)2 | 1,262 | 1,232 | 1,228 | 1,387 | 1,195 | 1,143 | 1,126 | 1,308 | |||||
Adjusted SSG&A Expense (% of Revenues)(%) | 23.9% | 24.7% | 26.0% | 26.4% | 23.9% | 24.2% | 25.1% | 25.3% | |||||
GAAP SSG&A Expense (% of Revenues)(%) | 23.9% | 25.3% | 25.7% | 26.5% | 24.1% | 24.6% | 24.9% | 25.5% | |||||
Adjusted R&D Expense — Non-GAAP ($M)($M)2 | 243 | 254 | 246 | 303 | 261 | 228 | 230 | 305 | |||||
Adjusted R&D Expense (% of Revenues)(%) | 4.6% | 5.1% | 5.2% | 5.8% | 5.2% | 4.8% | 5.1% | 5.9% | |||||
GAAP R&D Expense (% of Revenues)(%) | 4.7% | 5.2% | 5.3% | 5.8% | 5.3% | 4.9% | 5.2% | 6.6% | |||||
Adjusted Net Income from Continuing Operations — Non-GAAP ($M)($M)6 | 1,136 | 888 | 816 | 716 | 937 | 884 | 804 | 808 | |||||
Adjusted Net Margin (% of Revenues)(%) | 21.5% | 17.8% | 17.3% | 15.8% | 18.7% | 18.7% | 17.9% | 19.3% | |||||
GAAP Net Margin (% of Revenues)(%) | 13.1% | 9.1% | -0.8% | 7.3% | 6.9% | 9.5% | 3.5% | 5.9% | |||||
Adjusted Income Tax Provision — Non-GAAP ($M)($M) | 231 | 203 | 173 | 111 | 177 | 201 | 173 | 74 | |||||
Adjusted Effective Tax Rate (%)(%) | 16.9% | 18.6% | 17.5% | 11.8% | 15.9% | 18.5% | 17.7% | 6.9% | |||||
GAAP Effective Tax Rate (%)(%) | 23.2% | 18.5% | 193.1% | 2.8% | 1.9% | 20.8% | 21.5% | 0.9% | |||||
Adjusted Diluted EPS from Continuing Operations — Non-GAAP ($)($)1 | 4.15 | 3.23 | 2.90 | 2.50 | 3.26 | 3.08 | 2.79 | 2.78 | 3.81 | 12.21 | 12.21 | 12.21 | |
Reported GAAP Diluted EPS from Continuing Operations ($)($) | 2.52 | 1.09 | 1.20 | 1.57 | 0.55 | 0.50 | |||||||
LTM Adjusted EBITDA — Continuing Operations ($M)($M)2 | 5,842 | 5,609 | 5,609 | 5,561 | |||||||||
Net Debt (Total Debt Less Cash & Short-Term Investments, $M)($M) | 15,611 | 16,099 | 16,463 | 14,928 | |||||||||
Net Leverage Ratio (Net Debt / LTM Adjusted EBITDA, x)(×) | 2.70 | 2.90 | 2.90 | 2.70 | |||||||||
Inventories by Production Stage — Total ($M)($M)3 | 3,191 | 3,316 | 3,357 | 4,085 | 3,149 | 3,949 | 3,723 | 3,860 | 3,843 | 3,255 | 3,229 | 3,304 | |
Finished Products Inventory ($M)($M) | 2,122 | 2,161 | 2,650 | 2,071 | 2,518 | 2,344 | 2,502 | 2,597 | 2,087 | 2,076 | 2,160 | ||
Work in Process Inventory ($M)($M) | 401 | 396 | 495 | 354 | 512 | 487 | 453 | 443 | 406 | 376 | 368 | ||
Materials & Supplies (Raw Materials) Inventory ($M)($M) | 793 | 801 | 940 | 724 | 920 | 892 | 904 | 803 | 763 | 777 | 776 | ||
Property, Plant & Equipment, Gross ($M)($M)2 | 13,604 | 13,552 | 15,237 | 13,656 | 14,854 | 14,409 | 14,156 | 14,378 | 13,922 | 13,925 | 13,899 | ||
Accumulated Depreciation & Amortization on PP&E ($M)($M) | 7,521 | 7,470 | 8,265 | 7,272 | 8,036 | 7,763 | 7,554 | 7,557 | 7,404 | 7,334 | 7,253 | ||
Property, Plant & Equipment, Net ($M)($M) | 6,191 | 6,083 | 6,082 | 6,972 | 6,383 | 6,818 | 6,646 | 6,602 | 6,821 | 6,518 | 6,591 | 6,647 | |
Acquired Intangible Assets (Excl. Goodwill), Gross ($M)($M)8 | 21,323 | 21,289 | 22,673 | 21,575 | 22,636 | 22,544 | 22,486 | 22,525 | 21,126 | 21,119 | 21,119 | ||
Restructuring Liability Reserve Balance — Total ($M)($M)4 | 73 | 79 | 76 | 58 | 76 | 74 | 53 | 60 | 42 | 70 | 81 | ||
Restructuring Reserve — Employee Termination & Severance ($M)($M) | 31 | 31 | 47 | 31 | 63 | 51 | 47 | 58 | 41 | 69 | 80 | ||
Restructuring Reserve — Other Restructuring & Plant Exit ($M)($M) | 42 | 48 | 29 | 27 | 13 | 23 | 6 | 2 | 1 | 1 | 1 | ||
Restructuring Accrual Charges Recorded ($M)($M) | 48 | 482 | 75 | 88 | 58 | 63 | 66 | 125 | 95 | 98 | 69 | ||
Restructuring Cash Payments Settled ($M)($M) | 37 | 36 | 58 | 73 | 54 | 39 | 65 | 85 | 76 | 79 | 65 | ||
Share Repurchases — Total Common Shares Repurchased (millions)(M)2 | -3.21 | 9.32 | 1.31 | 0.62 | 2.64 | 2.12 | |||||||
Cash Paid for Common Share Repurchases ($M)($M) | 0 | 2,000 | 250 | 250 | 0 | 0 | 750 | 0 | 0 | 0 | 500 | ||
Remaining Share Repurchase Authorization (million shares)(M) | 8.30 | 11.5 | 11 | 12 | 13 | 13 | 4 | ||||||
Share-Based Compensation Expense — Total ($M)($M) | 55 | 73 | 91 | 54 | 55 | 59 | 90 | 50 | 54 | 60 | 83 | ||
Product Liability & Legal Matters Accrual Reserve Balance ($M)($M)5 | 1,600 | 1,700 | 1,700 | 1,800 | 1,900 | 1,700 | 1,700 | 1,800 | |||||
BD Pyxis / Alaris Product Remediation Liability Balance ($M)($M) | 68 | 83 | 98 | 114 | 124 | 50 | 28 | ||||||
Hernia Repair Mesh Product Liability Pending Claims (count) | 7,090 | 6,995 | 6,905 | 6,905 | 6,845 | 6,790 | 6,670 | 6,610 | 38,800 | 37,330 | 35,935 | ||
Implantable Port Product Liability Pending Claims (count) | 3,850 | 3,250 | 2,765 | 2,380 | |||||||||
Ethylene Oxide (EtO) Sterilization Pending Lawsuits (count) | 435 | 430 | 420 | 390 | 390 | 360 | 235 | 235 | |||||
Ethylene Oxide (EtO) Pending Plaintiffs (count) | 445 | 440 | 430 | 400 | 400 | 375 | 350 | 350 | |||||
Diagnostic Solutions Organizational Unit (Legacy through FY2026Q1) — Worldwide Revenue ($M)($M)5 | 439 | 498 | 425 | 440 | 474 | 481 | 429 | 468 | 467 | ||||
Biosciences Organizational Unit (Legacy through FY2026Q1) — Worldwide Revenue ($M)($M)5 | 327 | 387 | 358 | 352 | 361 | 397 | 363 | 377 | 375 | ||||
Discontinued Operations (BDS Spin-Off) — Revenues Reported by BD ($M)1 | |||||||||||||
FDA 510(k) Premarket Notifications Cleared — BD & C.R. Bard1 | 4 | 6 | 5 | 4 | 9 | 9 | 7 | 6 | 1 | 2 | 4 | 6 | |
FDA 510(k) Premarket Notifications Cleared — U.S. MedTech Industry Total | 855 | 923 | 756 | 806 | 797 | 886 | 736 | 856 | 767 | 793 | 713 | 877 | |
FDA Premarket Approvals (PMA & Supplements) — BD & C.R. Bard1 | 6 | 9 | 2 | 2 | 4 | 3 | 5 | 4 | 0 | 2 | 2 | 4 | |
FDA Premarket Approvals (PMA & Supplements) — U.S. MedTech Industry Total | 565 | 608 | 567 | 525 | 585 | 588 | 524 | 683 | 538 | 550 | 459 | 656 | |
FDA openFDA Device Recall Records — BD & C.R. Bard1 | 1 | 15 | 1 | 8 | 5 | 11 | 2 | 21 | 6 | 1 | 34 | 6 | |
FDA Device Enforcement Reports — BD & C.R. Bard | 1 | 15 | 1 | 8 | 15 | 1 | 7 | 18 | 4 | 3 | 32 | 6 | |
FDA MAUDE Adverse Event Reports — BD & C.R. Bard Total4 | 4,044 | 3,576 | 3,570 | 4,885 | 11,409 | 4,322 | 3,900 | 3,963 | 3,202 | 3,274 | 3,533 | 4,413 | |
U.S. PPI: Surgical & Medical Instrument Manufacturing (Index)1 | |||||||||||||
Interventional — Segment Revenue ($M, DB)($M)1 | 1,472 | 1,414 | 1,357 | 1,330 | 1,367 | 1,328 | 1,264 | 1,257 | 1,260 | 1,240 | 1,292 | 1,188 | |
United States — Consolidated Revenue ($M, DB)($M)1 | 3,081 | 2,917 | 3,159 | 3,422 | 3,181 | 3,108 | 3,080 | 3,117 | 2,891 | 2,906 | 2,749 | ||
Consolidated Revenues ($M, DB)($M)16 | 5,274 | 4,983 | 4,714 | 4,486 | 5,005 | 4,726 | 4,480 | 4,333 | 5,437 | 4,990 | 5,045 | 4,706 | |
Total Assets ($M, DB)($M)10 | 50,791 | 50,731 | 50,832 | 54,841 | 55,325 | 54,902 | 54,467 | 54,665 | 57,286 | 55,582 | 54,157 | 52,274 | |
Operating Cash Flow — Continuing Operations ($M, DB)($M)5 | 776 | 671 | 657 | 1,852 | 1,089 | -204 | 693 | 1,178 | 1,297 | 514 | 855 | ||
26 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Core Operational & Organizational Unit KPIs (Groups 1–2): Consolidated MD&A revenue growth decomposition into Volume/Mix (%), Pricing (%), and Foreign Currency (%); New BD organic vs. inorganic M&A revenue bridges; Remaining Performance Obligations (RPO) split between equipment/service installations ($2,756M at Q3 FY26) and minimum consumable commitments ($2,914M at Q3 FY26); customer contract & rebate liabilities; Developed Markets, Emerging Markets, and China revenues; and all 8 active organizational units across Worldwide, U.S., and International markets.
- FY2026 Segment Reorganization & Life Sciences Spin-Off (Groups 2, 3 & 6): Effective October 1, 2025 (FY2026), BD reorganized its businesses into 4 continuing reportable segments — Medical Essentials (MDS, Specimen Management), Connected Care (MMS, Advanced Patient Monitoring), BioPharma Systems, and Interventional (PI, UCC, Surgery) — and on February 9, 2026 completed the spin-off and Reverse Morris Trust combination of its Biosciences & Diagnostic Solutions (BDS) business with Waters Corporation (receiving a $4,000M cash distribution). Standalone carve-out financials and operational metrics of the BDS Business (Product vs. Service revenue, Placed Instruments, RPO, Rebates, and DS/BS segment P&Ls) are tracked in Group 6 alongside legacy Diagnostic Solutions, Biosciences, and Diabetes Care (embecta) unit series.
- Consolidated − Standalone Assessment (Step 3 & Step 4): Becton, Dickinson and Company files consolidated U.S. GAAP financial statements in Form 10-K/10-Q without parent-only Schedule I financial statements (restricted net assets of subsidiaries do not exceed 25% of consolidated net assets). Instead of parent subtraction, the separated BDS Business (SpinCo) is tracked directly from its audited carve-out financial statements (Form 8-K Exhibit 99.2 & Form 10-Q Exhibit 99.1) in Group 6, and UK operating subsidiaries Becton, Dickinson U.K. Limited (Co. 00852702) and Bard Limited (Co. 00939600) are tracked in Group 7.
- Period Splitting & Strict Formula Compliance (Step 4): Only YTD subtraction ('quarter = year-to-date − previous year-to-date' and 'Q4 = full year − nine months') is used where SEC filings report cumulative year-to-date cash flows, segment footnotes, or full-year totals. Zero self-computed ratios, margins, YoY rates, or sums exist anywhere in output/kpis.json.
Không hiện vì thiếu các kỳ gần đây (24)
- Consumables Share of Total Revenue ('over 90% of total revenue' in DEF 14A & Waters Transaction Deck) — Disclosed only as a lower bound ('>90%'); excluded per Step 5 bound rule.
- Customer Service Levels ('over 90%' / 'above 90%' in Q2–Q4 FY2026 Earnings Presentations & Transcripts) — Disclosed only as a lower bound ('>90%'); excluded per Step 5 bound rule.
- BD Excellence Annual Kaizen Events ('over 2,000 Kaizens' / 'more than 2,000 Kaizen events' in FY2026 Transcripts) — Disclosed only as a lower bound ('>2,000'); excluded per Step 5 bound rule.
- BD Excellence Plant Gross Productivity Improvement ('over 8%' in FY2025 Annual Report & DEF 14A; '~8%' in FY2026 Transcripts) — Disclosed as a bound in FY2025 ('over 8%') and approximate figure in FY2026; excluded per Step 5.
- GLP-1 & Biosimilar Drug Delivery Signed Customer Agreements ('over 80 deals' in Q2 FY2026; 'nearly 100 deals' in Q4 FY2026 Transcript) — Disclosed only as bounds ('over 80', 'nearly 100'); excluded per Step 5.
- Annual New Product Launches ('over 25 new product launches' in FY2025 DEF 14A & '100+ new product launches by FY2025') — Disclosed only with bound qualifiers ('over 25', '100+'); excluded per Step 5.
- U.S. & Puerto Rico Supplier Diversity Spend ($508M diverse-owned / 12% share, $809M small-business / 19% share in FY2022 ID&E Report; '$1.2+ billion' in FY2023 ESG Report) — Point figures disclosed only for a single year (FY2022) and as a bound ('$1.2+ billion') in FY2023 (<2 consecutive point years).
- Global Manufacturing Network Optimization Plant Count ('a little over 90 plants' in FY2022 to 'under 50 global sites' in FY2026 Q1/Q2 Transcripts, with 'over 20 plant closures' and 'a little over 20 plants going to Waters') — Disclosed only as bounds in earnings call commentary; exact Item 2 total facility count (379–431 sites) and square footage (27.0M–32.2M sq. ft.) are tracked in Group 7.
- Alaris Infusion System Category Market Share (~60% share in Q1 FY2026 Transcript; '>250 bps' FY2026 share gain in Q4 FY2026 Transcript; '85%' Pyxis Pro competitive conversions in Q1 FY2026) — Single-period point disclosures or bounds (<3 consecutive quarters); excluded per Step 5.
- Segment Expense Structure, Operating Margins & Capital Allocation (ASU 2023-07) › Medical Essentials — Segment Operating Income ($M) › Medical Essentials — Segment Capital Expenditures ($M)
- Segment Expense Structure, Operating Margins & Capital Allocation (ASU 2023-07) › Connected Care — Segment Operating Income ($M) › Connected Care — Segment Capital Expenditures ($M)
- Segment Expense Structure, Operating Margins & Capital Allocation (ASU 2023-07) › BioPharma Systems — Segment Operating Income ($M) › BioPharma Systems — Segment Capital Expenditures ($M)
- Non-GAAP Reconciliations, Net Leverage, Inventory Stages & Asset Schedules › Adjusted Net Income from Continuing Operations — Non-GAAP ($M) › Adjusted Diluted EPS from Continuing Operations — Non-GAAP ($) › Adjusted Diluted EPS Reported Growth YoY (%)
- Non-GAAP Reconciliations, Net Leverage, Inventory Stages & Asset Schedules › Adjusted Net Income from Continuing Operations — Non-GAAP ($M) › Adjusted Diluted EPS from Continuing Operations — Non-GAAP ($) › Adjusted Diluted EPS FX-Neutral Growth YoY (%)
- Product Remediation, Mass Tort Litigation Reserves & Regulatory Quality Inspections › Product Liability & Legal Matters Accrual Reserve Balance ($M) › Product Remediation Cost Estimate Adjustment Charge ($M)
- Spun-Off Biosciences & Diagnostic Solutions (BDS Business) & Legacy Divested Units › BDS Business (SpinCo Standalone) — Total Revenues ($M) › BDS Business — Placed Instruments at Customer Sites, Net ($M) › BDS Business — RPO: Service & Equipment Installations ($M)
- Spun-Off Biosciences & Diagnostic Solutions (BDS Business) & Legacy Divested Units › BDS Business (SpinCo Standalone) — Total Revenues ($M) › BDS Business — Placed Instruments at Customer Sites, Net ($M) › BDS Business — RPO: Minimum Consumable Commitments ($M)
- Spun-Off Biosciences & Diagnostic Solutions (BDS Business) & Legacy Divested Units › BDS Business (SpinCo Standalone) — Total Revenues ($M) › BDS Business — Placed Instruments at Customer Sites, Net ($M) › BDS Business — Customer Contract Liabilities ($M)
- Spun-Off Biosciences & Diagnostic Solutions (BDS Business) & Legacy Divested Units › Discontinued Operations (BDS Spin-Off) — Revenues Reported by BD ($M) › Discontinued Operations (BDS) — Income Before Income Taxes ($M)
- Spun-Off Biosciences & Diagnostic Solutions (BDS Business) & Legacy Divested Units › Discontinued Operations (BDS Spin-Off) — Revenues Reported by BD ($M)
- Manufacturing Footprint, Global Workforce, 3TG Supply Chain & Environmental Stewardship › Global Employees Headcount (associates) › U.S. Employees Headcount (associates)
- Manufacturing Footprint, Global Workforce, 3TG Supply Chain & Environmental Stewardship › Eligible 3TG Conflict Mineral Smelters & Refiners in Supply Chain — Total (count) › Gold Refiners Identified in Supply Chain (count) › RMAP-Conformant Gold Refiners (count)
- Manufacturing Footprint, Global Workforce, 3TG Supply Chain & Environmental Stewardship › Eligible 3TG Conflict Mineral Smelters & Refiners in Supply Chain — Total (count) › Tungsten Smelters Identified in Supply Chain (count) › RMAP-Conformant Tungsten Smelters (count)
- Manufacturing Footprint, Global Workforce, 3TG Supply Chain & Environmental Stewardship › Eligible 3TG Conflict Mineral Smelters & Refiners in Supply Chain — Total (count) › Tantalum Smelters Identified in Supply Chain (count) › RMAP-Conformant Tantalum Smelters (count)
Dữ liệu cập nhật 2026-11-07.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Organic Revenue Bridge, Contract Backlog (RPO) & Geographic Markets
- Consolidated Revenue Growth Bridge — Volume & Mix YoY (%) (%)15 kỳ
- New BD Continuing Operations — Organic Revenue ($M) ($M)8 kỳ
- Remaining Performance Obligations (RPO) — Service & Pending Equipment Installations ($M) ($M)19 kỳ
- Developed Markets Revenue ($M) ($M)12 kỳ
- Emerging Markets Revenue ($M) ($M)12 kỳ
- EMEA Region Revenue ($M) ($M)7 kỳ
Organizational Units & Segment Revenue Drivers (New BD Active Portfolio)
Segment Expense Structure, Operating Margins & Capital Allocation (ASU 2023-07)
- Medical Essentials — Segment Operating Income ($M) ($M)6 kỳ
- Connected Care — Segment Operating Income ($M) ($M)6 kỳ
- BioPharma Systems — Segment Operating Income ($M) ($M)6 kỳ
- Interventional — Segment Operating Income ($M) ($M)7 kỳ
- BD Medical Segment (Legacy through FY2025) — Segment Operating Income ($M) ($M)3 kỳ
- BD Life Sciences Segment (Legacy through FY2026Q1) — Segment Operating Income ($M) ($M)3 kỳ
- Unallocated Corporate Expenses & Shared Functions ($M) ($M)7 kỳ
Non-GAAP Reconciliations, Net Leverage, Inventory Stages & Asset Schedules
- Adjusted Gross Profit — Non-GAAP ($M) ($M)8 kỳ
- Adjusted Operating Income — Non-GAAP ($M) ($M)8 kỳ
- Adjusted Net Income from Continuing Operations — Non-GAAP ($M) ($M)8 kỳ
- LTM Adjusted EBITDA — Continuing Operations ($M) ($M)5 kỳ
- Inventories by Production Stage — Total ($M) ($M)71 kỳ
- Property, Plant & Equipment, Gross ($M) ($M)70 kỳ
- Acquired Intangible Assets (Excl. Goodwill), Gross ($M) ($M)66 kỳ
- Operating Lease Liabilities — Total ($M) ($M)5 kỳ
- Restructuring Liability Reserve Balance — Total ($M) ($M)32 kỳ
- Share Repurchases — Total Common Shares Repurchased (millions) (M)7 kỳ
- Share-Based Compensation Expense — Total ($M) ($M)19 kỳ
- Defined Benefit Pension Plans — Projected Benefit Obligation (PBO, $M) ($M)9 kỳ
Product Remediation, Mass Tort Litigation Reserves & Regulatory Quality Inspections
Spun-Off Biosciences & Diagnostic Solutions (BDS Business) & Legacy Divested Units
- BDS Business (SpinCo Standalone) — Total Revenues ($M) ($M)3 kỳ
- Diagnostic Solutions Organizational Unit (Legacy through FY2026Q1) — Worldwide Revenue ($M) ($M)17 kỳ
- Biosciences Organizational Unit (Legacy through FY2026Q1) — Worldwide Revenue ($M) ($M)40 kỳ
- Diabetes Care Organizational Unit — embecta (Legacy through FY2021Q4) — Worldwide Revenue ($M) ($M)24 kỳ
- Discontinued Operations (BDS Spin-Off) — Revenues Reported by BD ($M) ($M)0 kỳ
Manufacturing Footprint, Global Workforce, 3TG Supply Chain & Environmental Stewardship
- Global Manufacturing, Warehousing, Research & Admin Facilities (sites)11 kỳ
- Global Employees Headcount (associates)12 kỳ
- Eligible 3TG Conflict Mineral Smelters & Refiners in Supply Chain — Total (count)11 kỳ
- Scope 1 & 2 GHG Emissions — Market-Based (metric tonnes CO2e)6 kỳ
- Total Energy Consumption — Renewable & Non-Renewable (MWh)6 kỳ
- Total Water Withdrawals (cubic meters, m3)6 kỳ
- Total Nonhazardous Operational Waste Generated (metric tonnes)6 kỳ
External FDA Regulatory, Clinical Trials, Federal Procurement & Macro Benchmarks
- FDA 510(k) Premarket Notifications Cleared — BD & C.R. Bard154 kỳ
- FDA Premarket Approvals (PMA & Supplements) — BD & C.R. Bard154 kỳ
- FDA openFDA Device Recall Records — BD & C.R. Bard154 kỳ
- FDA MAUDE Adverse Event Reports — BD & C.R. Bard Total154 kỳ
- ClinicalTrials.gov Newly Started Clinical Studies — BD & C.R. Bard12 kỳ
- U.S. Federal Prime Contract Obligations — BD Total ($M) ($M)129 kỳ
- U.S. PPI: Surgical & Medical Instrument Manufacturing (Index) (×)141 kỳ
Reportable Segments & Geographic Context (Database)
Consolidated Financial Statements Context (Database)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Becton Dickinson
- BD Form 10-Q — FY2026Q3 ↗
- SEC 8-K FY2026Q4 ↗
- BD Form 10-K — FY2025 ↗
- BD Q4 FY2026 Earnings Presentation ↗
- U.S. FDA openFDA Device Clearances, PMA, Recalls & MAUDE — BD & C.R. Bard ↗
- SEC 8-K FY2026Q4 (2026-11-05) ↗
- BD Form 8-K Exhibit 99.1 Historical Segment Recast (filed 2026-02-05) ↗
- BD FY2025 Corporate Sustainability Report (New BD Continuing Operations) ↗
- SEC 8-K FY2026Q1 ↗
- USAspending.gov Federal Prime Contract Awards — Becton Dickinson ↗
- BD Form 10-Q (filed 2026-08-06) ↗
- BDS Business Audited Financial Statements (FY2023-FY2025, Waters 8-K Ex. 99.1) ↗
See a number that looks wrong?